WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services in India launched

The National Coordination Centre-Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India is the WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services. This is the first WHO Collaborating Centre on this theme globally.

This was announced at an event to mark the occasion at New Delhi on 30 October 2017.

The Pharmacovigilance Programme of India (PvPI) has progressed considerably in the last few years. The primary objective of the programme is to create a nation-wide system for patient safety reporting. There are 250 functioning Adverse Drug Monitoring centres in the country (in medical colleges and corporate hospitals) as part of PvPI.

Welcoming the announcement, Mr R.K. Vats, Additional Secretary, Ministry of Health & Family Welfare, said, “Integrating pharmacovigilance as an essential component of public health programmes is crucial for patient safety.”

Speaking on the occasion, Dr Clive Ondari, Coordinator, Safety & Vigilance, WHO said, “India’s concerted efforts in the area of pharmacovigilance have been recognized by WHO. It has also been highlighted that the country needs to play a bigger role in the global landscape of adverse drug reaction (ADR) monitoring, thus making India a hub for pharmacovigilance in public health programmes and regulatory services.”

This announcement is particularly significant as the pharmaceutical sector is one of the key 25 sectors identified by the Government of India under the ambitious ‘Make in India’ initiative, which is likely to provide the necessary impetus to the sector in order to achieve its true potential. At present, globally, the Indian pharmaceuticals industry is the third largest in volume and the tenth largest in value.

The event also saw the launch of the ‘National Strategic Plan for Scale up of Pharmacovigilance in India’ and ‘Pharmacovigilance Guidelines for Stakeholders’.

Indian Pharmacopoeia Commission through National Coordination Centre, Pharmacovigilance Programme of India is one of the active member countries in WHO-Programme of International Drug Monitoring and is also leading the thematic area of Vigilance as part of the South East Asia Regulatory Network (SEARN).

Share